On the 27th December 2012, Parexel announced they had completed the purchase of Regulatory Submissions experts Liquent for $72m from Marlin Equity Partners. Liquent is a global provider of Regulatory Information Management solutions to more than 200 biopharmaceutical and life science companies across the globe. Liquent currently have offices based in Pennsylvania (Headquaters), UK, Germany and India. Liquent currently employ nearly 300 staff.
The purchase gives Parexel access to Liquents flagship software InSight. The software will give Parexel clients access to a comprehensive regulatory-submission planning, viewing, tracking, publishing and registrations management throughout the entire lifecycle of any given medical entity. Liquent is expected to contribute very little revenue to Parexel initially with Q2 2013 forecast to be around $17m and $23m of service revenue during the second half of the year.
The purchase of Liquent will not only expand Parexels regulatory offering but enhance the capabilities of Parexel’s Perspective Informatics Unit and its consulting and medical communications service.
To read the full press release please click here